|

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

RECRUITINGPhase 2Sponsored by University Health Network, Toronto
Actively Recruiting
PhasePhase 2
SponsorUniversity Health Network, Toronto
Started2023-07-31
Est. completion2031-08
Eligibility
Age18 Years – 100 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05656794

Summary

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Eligibility

Age: 18 Years – 100 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Histologically-proven metastatic prostate cancer
* Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
* Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
* Planned for EBRT
* ECOG 0 or 1
* Age 18 years or older

Exclusion Criteria:

* Prior radiotherapy to pelvis
* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
* Any condition where radiotherapy is contraindicated

Conditions2

CancerProstate Metastases

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.